事実根拠 8
Suzhou Ribo Life Science (06938.HK) und seine Tochtergesellschaft Ribocure Pharmaceuticals AB (zusammen als „Ribo" bezeichnet)
PR Newswire news releases · 2026-11-10 13:59
証拠を見る
- 企業開示PR Newswire news releases2026-11-10 13:59
Suzhou Ribo Life Science (06938.HK) und seine Tochtergesellschaft Ribocure Pharmaceuticals AB (zusammen als „Ribo" bezeichnet)
出典を見る - 企業開示PR Newswire news releases2026-11-10 09:00
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB
出典を見る - 企業開示PR Newswire news releases2026-11-10 09:00
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo")
出典を見る - 企業開示PR Newswire news releases2026-10-09 06:56
Suzhou Ribo Life Science (06938.HK) und seine Tochtergesellschaft Ribocure Pharmaceuticals AB (zusammen als „Ribo" bezeichnet)
出典を見る - 企業開示PR Newswire news releases2026-10-09 06:56
Als ausländische Tochtergesellschaft von Suzhou Ribo Life Science
出典を見る - 企業開示PR Newswire news releases2026-10-08 18:44
Como filial en el extranjero de Suzhou Ribo Life Science, Ribocure Pharmaceuticals AB (Ribocure) se dedica al desarrollo global de terapias con oligonucleótidos que salvan vidas.
出典を見る - 企業開示PR Newswire news releases2026-10-08 10:57
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB
出典を見る - 企業開示PR Newswire news releases2026-10-08 09:41
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB
出典を見る